Sima Rasti1, Malihe Hassanzadeh1, Hossein Hooshyar1, Mansooreh Momen-Heravi2,3, Seyed Gholam Abbas Mousavi4, Amir Abdoli5. 1. a Department of Parasitology and Mycology, Faculty of Medicine , Kashan University of Medical Sciences , Kashan , Iran. 2. b Department of Infectious Disease, Faculty of Medicine , Kashan University of Medical Sciences , Kashan , Iran. 3. c Infectious Disease Research Center, Faculty of Medicine , Kashan University of Medical Sciences , Kashan , Iran. 4. d Department of Statistics and Public Health, Faculty of Health , Kashan University of Medical Sciences , Kashan , Iran. 5. e Department of Parasitology, Faculty of Medical Science , Tarbiat Modares University , Tehran , Iran.
Abstract
INTRODUCTION: Intestinal parasitic infections (IPIs) are important causes of morbidity and mortality in patients with immunocompromising conditions. OBJECTIVE: The aim of this study was to determine the prevalence of IPIs in different groups of immunocompromised patients, including hemodialysis patients (HD), renal transplant recipients (RTR), cancer and HIV/AIDS patients in comparison with healthy individuals in two central cities of Iran (Kashan and Qom). METHODS: In this case-control study, the stool samples of 135 HD, 50 RTR, 60 cancer patients, 20 HIV/AIDS patients and 120 healthy subjects were tested using direct-smear, formol-ether concentration, Ziehl-Neelsen staining and Agar plate method. RESULTS: The overall infection rate was 11.7% (31/265) in patient groups and 0% (0/120) in the control group. The frequency of parasites was 25% in HIV/AIDS patients, 11.9% (16/135) in HD, 12.0% (6/50) in RTR and 6.7% (4/60) in cancer patients. Blastocystis hominis (4.2%) and Giardia lamblia (3.0%) were the most prevalent parasites in patient groups. The infection rate was significantly higher in male (17.6%) than female (5.4%) patients (p = .002), but no statistically significant association was observed according to the age and educational levels. CONCLUSIONS: This study showed a high prevalence of IPIs in immunocompromised patients. The results of this study suggest that periodic stool examinations for screening of IPIs should be included as a part of routine medical care in these patients.
INTRODUCTION:Intestinal parasitic infections (IPIs) are important causes of morbidity and mortality in patients with immunocompromising conditions. OBJECTIVE: The aim of this study was to determine the prevalence of IPIs in different groups of immunocompromised patients, including hemodialysis patients (HD), renal transplant recipients (RTR), cancer and HIV/AIDSpatients in comparison with healthy individuals in two central cities of Iran (Kashan and Qom). METHODS: In this case-control study, the stool samples of 135 HD, 50 RTR, 60 cancerpatients, 20 HIV/AIDSpatients and 120 healthy subjects were tested using direct-smear, formol-ether concentration, Ziehl-Neelsen staining and Agar plate method. RESULTS: The overall infection rate was 11.7% (31/265) in patient groups and 0% (0/120) in the control group. The frequency of parasites was 25% in HIV/AIDSpatients, 11.9% (16/135) in HD, 12.0% (6/50) in RTR and 6.7% (4/60) in cancerpatients. Blastocystis hominis (4.2%) and Giardia lamblia (3.0%) were the most prevalent parasites in patient groups. The infection rate was significantly higher in male (17.6%) than female (5.4%) patients (p = .002), but no statistically significant association was observed according to the age and educational levels. CONCLUSIONS: This study showed a high prevalence of IPIs in immunocompromised patients. The results of this study suggest that periodic stool examinations for screening of IPIs should be included as a part of routine medical care in these patients.
Authors: Ali Taghipour; Taher Azimi; Ehsan Javanmard; Ali Pormohammad; Meysam Olfatifar; Ali Rostami; Payam Tabarsi; Mohammad Reza Sohrabi; Hamed Mirjalali; Ali Haghighi Journal: Gastroenterol Hepatol Bed Bench Date: 2018
Authors: Maria do Rosário A Silva; Gessica B Melo; Fernanda M Malta; Edson Abdala; Silvia F Costa; Ligia C Pierrotti; Elenice M N Gonçalves; Vera L P Castilho; Pedro P Chieffi; Ronaldo C B Gryschek; Fabiana M Paula Journal: Parasite Epidemiol Control Date: 2019-11-27